We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: *** ACAD REPORT ***

No earlier versions found for this Subject.

Return to *** ACAD REPORT ***
ACADIA Pharmaceuticals, Inc. has since a staggering day of trading on Novemeber 27 with 60 million plus shares exchanging hands been awarded two new price targets by analysts one for $9 and the other for $8.50. Also two non price target upgrades were awarded.

ACAD's drug is probably going to be the first true Parkinson's disease psychosis treatment. The market will rapidly change its perspective on ACAD due to the recent results, which prove that the drug actually works! The drug is the company's most advanced and if approved currently has no competition in the marketplace. Those who were treated with pimavanserin, a 5.79-point reduction in psychotic behavior was observed, compared to a 2.73-point reduction in the control group. These results are statistically significant!

The report recommends accumulation of ACAD. What surges in heavy volume biopharma usually has a reason with follow threw volume and large share increase in the not so distant future.

ACAD is therefore awarded: MARKET OUTPERFORM